A survey of Japanese thoracic oncologists' perception of diagnostic and treatment strategies for EGFR mutant or EML4-ALK fusion non-small cell lung cancer.
نویسندگان
چکیده
To the Editor: In non-small cell lung cancer (NSCLC), several driver oncogenes, including epidermal growth factor receptor (EGFR) and echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK), have been found. Th is has led to the development of personalized therapy with EGFRor ALKtyrosine kinase inhibitor (TKI); however, in clinical practice, oncologists’ perceptions of the diagnostic and treatment strategies have not been fully assessed.
منابع مشابه
Dual drive coexistence of EML4‐ALK and TPM3‐ROS1 fusion in advanced lung adenocarcinoma
We report a case of concomitant EML4-ALK and TPM3-ROS1 fusion in non-small cell lung cancer (NSCLC) in a 47-year-old Chinese man and review the clinical characteristics of this type double of fusion. The patient presented with a local tumor of the left upper lobe and underwent thoracoscopy. Postoperative surgical pathologic staging revealed T1a N0 M0 stage IA. Histological examination of the tu...
متن کاملClinical outcomes of thoracic radiotherapy for locally advanced NSCLC with EGFR mutations or EML4-ALK rearrangement.
BACKGROUND Little is known about the occurrence and consequences of epidermal growth factor receptor gene (EGFR) mutations and the fusion of the echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK) genes in locally advanced non-small cell lung cancer (NSCLC). PATIENTS AND METHODS We retrospectively examined 37 patients with locally advanced NSCLC treate...
متن کاملDetection of EML4-ALK fusion gene and features associated with EGFR mutations in Chinese patients with non-small-cell lung cancer.
PURPOSE Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) and epidermal growth factor receptor (EGFR) define specific molecular subsets of lung cancer with distinct clinical features. We aimed at revealing the clinical features of EML4-ALK fusion gene and EGFR mutation in non-small-cell lung cancer (NSCLC). METHODS We enrolled 694 Chinese patients with NSC...
متن کاملBetter Selection Model for EML4-ALK Fusion Gene Test in Patients with Non-Small-Cell Lung Cancer
Background: In the last decade, the search for gene mutations in lung cancer has been constantly growing. EGFR, KRAS mutations and, recently, the EML4-ALK fusion can guide the selection of treatment for patients who carry a specific mutation. Methods: During 2010-2011, EML4-ALK fusion test has been performed in Israel, mostly for wild type EGFR non-squamous NSCLC patients based on fluorescent i...
متن کاملAnaplastic lymphoma kinase gene rearrangement and non-small cell lung cancer management: a step forward in personalized therapy
We greatly enjoyed reading the thought-provoking article by Lopes et al. in a recent issue of your esteemed journal (1). Interestingly, in recent years, data have emerged regarding a role for EML4 (echinoderm microtubule-associated protein-like 4)–ALK (anaplastic lymphoma kinase) in personalized treatment for advanced non-small-cell lung cancer (NSCLC) (2,3). EML4-ALK undergoes constitutive dim...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Chest
دوره 146 6 شماره
صفحات -
تاریخ انتشار 2014